Details of the Drug Combinations

General Information of This Drug (ID: DM1WEHC)

• Drug Name: Buparlisib (DM1WEHC)
• Synonyms: BKM120

Indication

Breast cancer; ICD 11: 2C60-2C65; Status: Phase 3 [1]

• Drug Type: Small molecular drug

List of Combinatorial Drugs (CBD) Containing This Drug

50 Investigative Drug Combination(s) Consisting of This drug

Normalized Drug Combination Synergy Score

Synergy scores were normalized using Min-Max Scaling to facilitate visual comparisons.

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
(-)-englerin A + Buparlisib	DCQA23U	(-)-englerin A	Ewing sarcoma (Cell Line: TC-71)	[2]
ABT-263 + Buparlisib	DCAZWM4	ABT-263	Ewing sarcoma (Cell Line: TC-71)	[3]
Afatinib + Buparlisib	DCIFZAP	Afatinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
AXL-1717 + Buparlisib	DCDDOO6	AXL-1717	Ewing sarcoma (Cell Line: TC-71)	[2]
Bafilomycin A1 + Buparlisib	DCGC2BD	Bafilomycin A1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
BMS-754807 + Buparlisib	DCP69GY	BMS-754807	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + JQ1	DC12CEJ	JQ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + Carfilzomib	DCHJBV2	Carfilzomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + Panobinostat	DCO8C2N	Panobinostat	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + Ixazomib	DCNUSCU	Ixazomib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + Alvespimycin hydrochloride	DCO1U3K	Alvespimycin hydrochloride	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + THZ1	DCCATEQ	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + AZD8330	DC54EJP	AZD8330	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Buparlisib + Ruxolitinib	DC7JIUH	Ruxolitinib	Hodgkin lymphoma (Cell Line: L-1236)	[3]
Buparlisib + Trametinib	DC7JHAI	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[3]
Buparlisib + Trametinib	DCBOJNT	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
Buparlisib + Trametinib	DCLVFQ1	Trametinib	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
Buparlisib + Cotellic	DCJ2V56	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: Rh36)	[3]
Buparlisib + Cotellic	DCRD7BW	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: CTR)	[3]
Buparlisib + Cotellic	DC1URIC	Cotellic	Embryonal rhabdomyosarcoma (Cell Line: RD)	[3]
Cabozantinib + Buparlisib	DCH8AAI	Cabozantinib	Ewing sarcoma (Cell Line: TC-71)	[2]
Carfilzomib + Buparlisib	DCHI101	Carfilzomib	Ewing sarcoma (Cell Line: TC-71)	[2]
CF102 + Buparlisib	DCF81N6	CF102	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Dasatinib + Buparlisib	DCT815U	Dasatinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Decitabine + Buparlisib	DCFPLRW	Decitabine	Ewing sarcoma (Cell Line: TC-71)	[2]
Epothilone D + Buparlisib	DCJ7CSV	Epothilone D	Ewing sarcoma (Cell Line: TC-71)	[2]
Erlotinib + Buparlisib	DCB42SD	Erlotinib	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Ispinesib + Buparlisib	DCIUV2U	Ispinesib	Ewing sarcoma (Cell Line: TC-71)	[2]
Lestaurtinib + Buparlisib	DC4BKF1	Lestaurtinib	Ewing sarcoma (Cell Line: TC-71)	[2]
Mebendazole + Buparlisib	DCB16UJ	Mebendazole	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
MK-1775 + Buparlisib	DCUI7RF	MK-1775	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
MK-1775 + Buparlisib	DCJ0YKH	MK-1775	Ewing sarcoma (Cell Line: TC-71)	[2]
MK-2206 + Buparlisib	DCUMDDT	MK-2206	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
NVP-AUY922 + Buparlisib	DC4UCKL	NVP-AUY922	Ewing sarcoma (Cell Line: TC-71)	[2]
Ombrabulin + Buparlisib	DCVIG6M	Ombrabulin	Ewing sarcoma (Cell Line: TC-71)	[2]
ONC201 + Buparlisib	DCF4PWQ	ONC201	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Panobinostat + Buparlisib	DCOSNCD	Panobinostat	Ewing sarcoma (Cell Line: TC-71)	[2]
Pelitinib + Buparlisib	DC8RO3Z	Pelitinib	Ewing sarcoma (Cell Line: TC-71)	[2]
PHA-739358 + Buparlisib	DC98ET9	PHA-739358	Ewing sarcoma (Cell Line: TC-71)	[2]
PHA848125 + Buparlisib	DCJINQW	PHA848125	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Prochlorperazine + Buparlisib	DCDSFFX	Prochlorperazine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Romidepsin + Buparlisib	DCIIDC4	Romidepsin	Ewing sarcoma (Cell Line: TC-71)	[2]
SCH-900776 + Buparlisib	DCBSSGQ	SCH-900776	Ewing sarcoma (Cell Line: TC-71)	[2]
Steroid derivative 1 + Buparlisib	DC4OTD0	Steroid derivative 1	Ewing sarcoma (Cell Line: TC-71)	[2]
Teriflunomide + Buparlisib	DCENDT8	Teriflunomide	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
THAPSIGARGIN + Buparlisib	DCG1ESX	THAPSIGARGIN	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
THAPSIGARGIN + Buparlisib	DCXROIL	THAPSIGARGIN	Ewing sarcoma (Cell Line: TC-71)	[2]
THZ1 + Buparlisib	DCKWFF1	THZ1	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Tosyl-l-arginine methyl ester + Buparlisib	DCZF86F	Tosyl-l-arginine methyl ester	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]
Vincristine + Buparlisib	DCJPCMX	Vincristine	Diffuse intrinsic pontine glioma (Cell Line: DIPG25)	[2]

13 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
Buparlisib + Irinotecan	DCAEEWR	Irinotecan	Colorectal Cancer	[4]
Buparlisib + Paclitaxel	DCMXPBN	Paclitaxel	Breast Cancer	[5]
Buparlisib + Trametinib	DCR3LLR	Trametinib	Advanced and Selected Solid Tumors	[6]
Buparlisib + Oxaliplatin	DCWF9PL	Oxaliplatin	Advanced Solid Tumors	[7]
Buparlisib + Everolimus	DCWJ6CN	Everolimus	Solid Tumors	[8]
Buparlisib + Letrozole	DCX0RQ4	Letrozole	Metastatic Breast Cancer	[9]
Buparlisib + Imatinib	DCXX7IF	Imatinib	3rd Line GIST	[10]
Buparlisib + Letrozole	DC35L9F	Letrozole	Advanced or Metastatic Breast Cancer	[11]
Buparlisib + Docetaxel	DCBVG9K	Docetaxel	Squamous Non-small Cell Lung Cancer	[12]
Buparlisib + Ibrutinib	DCC1EFA	Ibrutinib	Lymphoma	[13]
Buparlisib + Lomustine	DCNJSM4	Lomustine	Recurrent Glioblastoma Multiforme	[14]
Fulvestrant + Buparlisib	DC3EXII	Fulvestrant	Estrogen Receptor-positive Breast Cancer	[15]
Fulvestrant + Buparlisib	DC2YQEC	Fulvestrant	Breast Cancer	[16]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7878).
• [2] Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
• [3] Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
• [4] ClinicalTrials.gov (NCT01304602) A Trial of Irinotecan and BKM120 in Previously Treated Advanced Colorectal Cancer
• [5] ClinicalTrials.gov (NCT01572727) A Study of the Experimental Drug BKM120 With Paclitaxel in Patients With HER2 Negative, Locally Advanced or Metastatic Breast Cancer, With or Without PI3K Activation
• [6] ClinicalTrials.gov (NCT01155453) A Study to Investigate Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of BKM120 Plus GSK1120212 in Selected Advanced Solid Tumor Patients
• [7] ClinicalTrials.gov (NCT01571024) BKM120 + mFOLFOX6 in Advanced Solid Tumors With Expansion Cohort Pancreatic Cancer
• [8] ClinicalTrials.gov (NCT01470209) A Phase I Study of BKM120 and Everolimus in Advanced Solid Malignancies
• [9] ClinicalTrials.gov (NCT01248494) PhIb BKM120 or BEZ235+Endocrine Treatment in Post-Menopausal Patients With Hormone Receptor + Metastatic Breast Cancer
• [10] ClinicalTrials.gov (NCT01468688) A Dose-finding Study of a Combination of Imatinib and BKM120 in the Treatment of 3rd Line GIST Patients
• [11] ClinicalTrials.gov (NCT02154776) Dose Escalation Study of LEE011 in Combination With Buparlisib and Letrozole in HR+, HER2-negative Post-menopausal Women With Advanced Breast Cancer.
• [12] ClinicalTrials.gov (NCT01911325) Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients
• [13] ClinicalTrials.gov (NCT02756247) A Clinical Trial of Buparlisib and Ibrutinib in Lymphoma
• [14] ClinicalTrials.gov (NCT01934361) Phase Ib/II Study of Buparlisib Plus Carboplatin or Lomustine in Patients With Recurrent Glioblastoma Multiforme
• [15] ClinicalTrials.gov (NCT01339442) BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer
• [16] ClinicalTrials.gov (NCT02088684) Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer